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Abstract
 
The parasitic protozoan 
 
Trypanosoma cruzi
 
 employs multiple molecular strategies to invade a
broad range of nonphagocytic cells. Here we demonstrate that the invasion of human primary
umbilical vein endothelial cells (HUVECs) or Chinese hamster ovary (CHO) cells overexpress-
 
ing the B
 
2 
 
type of bradykinin receptor
 
 
 
(CHO-B
 
2
 
R) by tissue culture trypomastigotes is subtly
modulated by the combined activities of kininogens, kininogenases, and kinin-degrading pepti-
dases. The presence of captopril, an inhibitor of bradykinin degradation by kininase II, drasti-
cally potentiated parasitic invasion of HUVECs and CHO-B
 
2
 
R, but not of mock-transfected
CHO cells, whereas the B
 
2
 
R antagonist HOE 140 or monoclonal antibody MBK3 to bradyki-
nin blocked these effects. Invasion competence correlated with the parasites’ ability to liberate
the short-lived kinins from cell-bound kininogen and to elicit vigorous intracellular free cal-
 
cium ([Ca
 
2
 
1
 
]
 
i
 
) transients through B
 
2
 
R. Invasion was impaired by membrane-permeable cys-
teine proteinase inhibitors such as Z-(SBz)Cys-Phe-CHN
 
2
 
 but not by the hydrophilic inhibitor
 
1-trans-epoxysuccinyl-
 
l
 
-leucyl-amido-(4-guanidino) butane or cystatin C, suggesting that ki-
nin release is confined to secluded spaces formed by juxtaposition of host cell and parasite
plasma membranes. Analysis of trypomastigote transfectants expressing various cysteine pro-
teinase isoforms showed that invasion competence is linked to the kinin releasing activity of
cruzipain, herein proposed as a factor of virulence in Chagas’ disease.
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Introduction
 
Chagas’ disease, the chronic infection by the parasitic pro-
tozoan 
 
Trypanosoma cruzi
 
,
 
 
 
is a major cause of cardiomyopa-
thy in rural Latin America. Transmitted by blood-sucking
triatomine insects, the infective forms of 
 
T. cruzi
 
 (trypo-
mastigotes) rapidly enter the bloodstream, from where they
disseminate the infection to multiple tissues. After invading
macrophages, muscle, and other nucleated cells, the trypo-
mastigotes escape from endocytic vacuoles and migrate into
the cytoplasm where they transform into round-shaped
amastigotes, the replicating forms. Within 5–6 d, the host
cells rupture, releasing large numbers of trypomastigotes
and amastigotes into interstitial spaces. Acute pathology and
parasite tissue load subside with the onset of immunity, but
the pathogen is not eradicated. After years of asymptomatic
infection, 10–24% of the patients develop a severe chronic
cardiomyopathy characterized by myocarditis, fibrosis, mi-
crocirculatory lesions, cardiomegaly, and conduction sys-
tem abnormalities (1–3).
At the cellular level, 
 
T. cruzi
 
 trypomastigotes invade
nonphagocytic cells by a unique mechanism distinct from
phagocytosis (4, 5). Penetration by tissue culture trypomas-
tigotes (TCTs)
 
1
 
 is preceded by energy-dependent adhesive
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Abbreviations used in this paper:
 
 ACE, angiotensin I–converting enzyme;
BK, bradykinin; [CA
 
2
 
1
 
]
 
i
 
, intracellular free calcium; CHO, Chinese ham-
ster ovary; DTT, dithiothreitol; H-kininogen, high molecular weight
kininogen; HUVEC, human primary umbilical vein endothelial cell;
TCT, tissue culture trypomastigote. 
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interactions (6) involving the parasites’ surface glycopro-
teins (7, 8) and negatively charged host surface molecules
(9). Depending on the host cell–parasite combination stud-
ied, invasion requires activation of the TGF-
 
b
 
 signaling
pathway (10) or stimulation of host cell receptors coupled
to heterotrimeric G proteins (11, 12). Efforts to character-
ize the hitherto unknown Ca
 
2
 
1
 
-signaling agonist pointed
to a crucial role of a cytosolic parasitic serine protease of 80
kD, oligopeptidase B (13). Although null mutants gener-
ated by targeted deletion of the oligopeptidase B gene were
poorly infective (14), purified or recombinant oligopepti-
dase B alone failed to induce intracellular free calcium
([Ca
 
2
 
1
 
]
 
i
 
)
 
 
 
transients in the mammalian cells (13). Because
addition of recombinant oligopeptidase B to null parasite
extracts reconstituted [Ca
 
2
 
1
 
]
 
i 
 
signaling, it was suggested
that the agonistic activity was generated by oligopeptidase
B–mediated processing of a cytoplasmic 
 
T. cruzi
 
 precursor
molecule (14).
Other clues to understand the role of 
 
T. cruzi
 
 proteases
in host cell invasion emerged from in vitro assays per-
formed with synthetic inhibitors of cruzipain (15), the par-
asite’s major cysteine proteinase (16–18). Encoded by mul-
tiple polymorphic genes (19, 20), this cathepsin L–like
proteinase is the most extensively characterized isoform ex-
pressed by replicating forms of the parasite (16–18, 21).
Given the broad pH range of the activity profile and the
high stability of cruzipain (17), the finding of antigen de-
posits of this molecule in foci of myocardial inflammation
(22) suggested that this proteinase may contribute to pa-
thology. Our findings that the substrate specificity of cruzi-
pain resembles that of tissue kallikrein and that cruzipain
releases the bradykinin (BK)-like vasoactive peptide lysyl-
bradykinin (“kallidin”) from its large precursor forms, high
(H-) and low (L-) molecular weight kininogens (23), sug-
gested that 
 
T. cruzi
 
 may directly trigger the kinin system
through the activity of this cysteine proteinase.
Here we demonstrate that the short-lived kinin peptides
and their cognate G protein–coupled cellular receptors (24)
are engaged in the signaling mechanisms leading to 
 
T. cruzi
 
invasion. We also show that invasion of cells that overex-
press the constitutive B
 
2
 
 subtype of BK receptor is critically
modulated by the kinin-degrading activity of host kininase
II, also known as the angiotensin I–converting enzyme
(ACE). The finding that activation of the proinflammatory
kinin cascade by trypomastigotes potentiates invasion may
shed light on the molecular basis of Chagas’ disease patho-
physiology.
 
Materials and Methods
 
Cells and Parasites.
 
Chinese hamster ovary (CHO) cells trans-
fected with the cDNA encoding the rat B
 
2 
 
type of BK receptor
 
(
 
B
 
2
 
R; CHO-B
 
2
 
R) or mock-transfected CHO cells (CHO-mock)
were used (25). Subclone rB2CHO12/4 showed a maximum
 
3
 
H-BK binding activity of 1.3 pmol/mg of protein at passage 2.
CHO cells were cultured in HAM’s F12, each supplemented
with 10% (vol/vol) of FCS at 37
 
8
 
C in a humidified atmosphere
containing 5% CO
 
2
 
. Vero cells were cultivated in DMEM with
 
10% FCS. Human primary umbilical vein endothelial cells (HU-
VECs) were obtained by treatment of umbilical veins with a 0.1%
(wt/vol) collagenase IV solution (Sigma-Aldrich). Primary HU-
VECs were seeded in 25-cm
 
2
 
 flasks (Corning) coated with 2%
porcine skin gelatin, and grown in M199 medium supplemented
with 2 mM glutamine, 2.5 
 
m
 
g/ml amphotericin B, 100 
 
m
 
g/ml
penicillin, 100 
 
m
 
g/ml gentamycin, 0.13% sodium bicarbonate,
and 20% FCS. Cells were maintained at 37
 
8
 
C in a humidified 5%
CO
 
2
 
 atmosphere until they reached confluency. After treatment
with 0.02% trypsin/0.02% EDTA, HUVECs were seeded into
24-well plates with gelatin-coated glass coverslips and cultivated
at 37
 
8
 
C for several days before being used in invasion assays.
 
T. cruzi
 
 epimastigotes (Dm28c clone) were cultivated at 28
 
8
 
C
in LIT medium containing 10% FCS. TCTs were harvested from
the supernatants of infected Vero cultures maintained in DMEM
supplemented with 2% FCS (TCT-FCS). TCT transfectants
overexpressing Dm28c genes encoding the major cruzipain (18)
isoform (for simplicity, hereafter designated cruzipain-1) or cruz-
ipain-2 (20, 23) were obtained by cloning full-length copies of
each of these into the SmaI-HindIII sites of pTEX plasmid (26).
Log phase Dm28c epimastigotes were transfected by electropora-
tion with a single pulse of 450 kV, 500 
 
m
 
F in an electroporator
(Bio-Rad Laboratories). The parasites were selected for growth
in LIT medium containing 10% FCS and 200 
 
m
 
g/ml of geneticin
(Sigma-Aldrich) for six consecutive weeks and reselected at 800
 
m
 
g/ml of geneticin for four additional weeks. Metacyclogenesis
was done by incubating stationary phase–transfected epimasti-
gotes in Grace’s medium, pH 5.5, including 800 
 
m
 
g/ml of gene-
ticin for 7 d at 27
 
8
 
C. TCT transfectants were collected from Vero
cell supernatants 3–4 d after infection with the metacyclics. Plas-
mid contents were stable for at least 7 wk of culture in the ab-
sence of the selecting drug; TCT transfectants were tested in in-
vasion assays after a 3-wk passage. The cysteine proteinase
activity contained in cell lysates from transfected or wild-type
parasites was measured as the rate of hydrolysis of 
 
e
 
-
 
l
 
-NH
 
2
 
-Cap-
 
l
 
-(SBz)C-MCA (20 
 
m
 
M) in Na
 
2
 
HPO
 
4
 
, 50 mM Na
 
2
 
HPO
 
4
 
, 200
mM NaCl, and 5 mM EDTA, pH 7.0, supplemented with 2.5
mM dithiothreitol (DTT), at 37
 
8
 
C. To prepare the parasite cell
lysates, freshly released TCTs were washed twice in HBSS and
resuspended in 300 
 
m
 
l of PBS, pH 7.2, containing 2 mM EDTA.
Then, parasites were subjected to freeze and thaw cycles (two
times), followed by the addition of Triton X-100 to 1%. Samples
were kept on ice for 10 min and soluble material was recovered
by centrifugation at 13,000 
 
g
 
. Protein concentration was deter-
mined by the Dc-protein kit (Bio-Rad Laboratories). Peptidase
activity was measured in lysates normalized to 2 
 
m
 
g/ml protein
(final concentration). Enzyme stability tests were performed by
mixing 2 
 
m
 
l of lysates (1 mg/ml) to 100 
 
m
 
l of 0.1 M glycine, pH
12, for 5 s. Assay buffer was added to 1 ml and the peptidase ac-
tivity was measured as described above.
 
Cell Invasion Assays.
 
CHO-B
 
2
 
R, CHO-mock, or native
HUVECs were plated on 13-mm round coverslips at a density of
2.5 
 
3
 
 10
 
4
 
 cells/cm
 
2
 
 in appropriate medium supplemented with
10% FCS and cultivated in 24-well plates for 48 h at 37
 
8
 
C in a
5% CO
 
2
 
 atmosphere. Before addition of TCTs, coverslips with
attached cells were washed three times with HBSS and kept in
serum-free medium containing 1 mg/ml BSA. The parasites
added to the wells were freshly released from cultures of infected
Vero cells cultivated in DMEM-FCS (2%). After removing cellu-
lar debris by low speed centrifugation (169 
 
g
 
), the parasite suspen-
sion was diluted three times in HBSS, spun down at 2,000 
 
g
 
, and
gently resuspended in DMEM-BSA or M199-BSA (1 mg/ml
each). Invasion assays with CHO cells or HUVECs were done in 
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a total volume of 0.6 ml of DMEM-BSA or M199-BSA, respec-
tively, at a parasite/host cell ratio of 2:1 for 3 h at 37
 
8
 
C, unless
otherwise specified. When required, the medium was supple-
mented with 25 
 
m
 
M of captopril (CAP medium). The effects of
receptor antagonists or antibodies were assayed by adding to CAP
medium 0.1 
 
m
 
M HOE 140 (Aventis), 5–100 nM BK (Calbio-
chem), or 200 nM of mAbs. In some experiments, CAP medium
was supplemented with purified H-kininogen (9 nM) 5 min be-
fore adding TCTs to HUVECs. Likewise, the effects of protease
inhibitors were tested by adding 10 or 75 
 
m
 
M 1-trans-epoxysuc-
cinyl-
 
l
 
-leucylamido-(4-guanidino) butane (E-64), 10 
 
m
 
M leu-
peptin (Sigma-Aldrich), 10 
 
m
 
M Z-(SBz)Cys-Phe-CHN
 
2 
 
(15), or
1 
 
m
 
M recombinant human cystatin C (from Dr. Magnus Abra-
hamson, Lund University, Lund, Sweden) to the CAP medium.
The effect of cruzipain-1 on invasion was evaluated by adding
10-fold dilutions of the activated protease to wells (0–10 nM final
concentration) immediately after the addition of the parasites.
The interaction was stopped by removing TCTs and washing
cells three times with HBSS. Monolayers were fixed with Bouin
and stained with Giemsa. Invasion was quantified by counting the
number of intracellular parasites in a total of 100 cells per cover-
slip. Values represent means 
 
6 
 
SD of at least three independent
experiments, each done in triplicate under “blinded” conditions.
Statistical analysis was done by one-way analysis of variance at a
 
P 
 
5
 
 0.05 significance level.
 
Digital Imaging Fluorescence Microscopy.
 
The changes in [Ca
 
2
 
1
 
]
 
i
 
were determined using the fluorescent dye Fura 2-AM (Molecu-
lar Probes). Customized chambers used in these experiments
were designed as follows: 30-mm plastic Petri dishes were drilled
leaving 1-cm diameter holes in the center covered at the bottom
by thin glass coverslips (0.7 mm) mounted with silicone glue.
The plates were extensively washed and sterilized under a UV
lamp for 20 min before use; coverslips for HUVECs contained
2% porcine gelatin. CHO cells and HUVECs were plated at 2 
 
3
 
105 cells per dish in the appropriate medium supplemented with
10 and 20% of FCS, respectively, and cultivated for 24 h at 378C
in 5% CO2. The monolayers were washed three times with
HBSS and incubated for 20 min at 378C in a 5% CO2 atmosphere
using serum-free HAM’s F12 medium, pH 7.4, supplemented
with 12.5 mM Hepes, 1 mg/ml BSA, 2.5 mM probenecid
(Sigma-Aldrich), 25 mM captopril, and 6 mM Fura 2-AM. After
rinsing three times to remove extracellular dye, the cells were
maintained at 378C for 15 min in the same medium without Fura
2-AM. Fura-loaded cells were analyzed in an Axiovert 100 mi-
croscope under an oil immersion 403 objective (ZEISS). Fluo-
rescence images were collected by a digital CCD camera using a
510-nm filter. [Ca21]i was monitored at 36–378C by alternating
the excitation wavelengths between 334 and 380 nm using the
Attofluor Ratio System (ZEISS). Raw fluorescence images were
digitalized to a pixel assay, point density readings were taken for
each image, and a visual display of the 340/380-nm ratio was
produced. Before adding parasites or purified proteases, the varia-
tion of [Ca21]i of all cells in the field was monitored for 2 min;
20–30 cells which did not present spontaneous [Ca21]i transients
were chosen as regions of interest. After initial monitoring, the
cellular responsiveness to kinin receptor agonists was assessed by
adding BK (5–50 nM) to CHO-B2R or HUVECs preloaded
with Fura 2-AM, using CAP medium. Vigorous [Ca21]i tran-
sients were observed for nearly 100% of the monitored cells.
Specificity of BK-induced transients was checked by adding 100
nM of HOE 140 to the monolayers before 50-nM agonist expo-
sure. CHO-mock failed to induce significant [Ca21]i elevations
up to 50 nM BK. When indicated, 100 nM of HOE 140 was ap-
plied to the cells before the application of enzyme or parasites.
Assays with TCTs were carried out at a parasite/host cell ratio of
10:1. Responding cells were observed under light phase to con-
firm interaction with the parasites. The Attograph software was
used to generate tracings representing [Ca21]i transients of indi-
vidual cell responses, as well as average responses of 20–30 cells
(n 5 30). Purified cruzipain-1 was tested at 5 nM, after a 15-min
activation of a stock solution (10-fold) with 2.5 mM DTT in
PBS, pH 7.2. Controls included the addition of DTT-containing
buffer alone or activated cruzipain-1 pretreated with 75 mM E-64
for 30 min. The specificity of HOE 140 was tested by pretreating
HUVECs with 100 nM of the B2R antagonist before stimulating
the cells with 14 nM a-thrombin (Dr. Russolina Zingali, Federal
University of Rio de Janeiro, Rio de Janeiro, Brazil) or with 50
nM BK. In the last series of experiments, the [Ca21]i concentra-
tions were determined by the two-point calibration in vivo
method (27) after sequentially adding 20 mM ionomycin (Sigma-
Aldrich) and 10 mM EGTA to the cultures.
Purified Proteins and Abs. Cruzipain (GP57/51) was isolated
from crude aqueous extracts of Dm28c epimastigotes as described
(28). Recombinant cruzain (cruzipain-1) lacking the COOH-
terminal extension (18) was expressed in Escherichia coli (Dr. J.H.
McKerrow, University of California at San Francisco, San Fran-
cisco, CA). Recombinant cruzipain-2 devoid of the COOH ter-
minus (20) was expressed in Saccharomyces cerevisiae (23) and
partially purified by affinity chromatography on thiolpropyl–
Sepharose 6B (Amersham Pharmacia Biotech); SDS-PAGE re-
vealed a major band of 29 kD. Purified H-kininogen was from
Calbiochem. mAbs MBK3 (IgG1) recognizing the BK epitope in
domain D4 of human and bovine H-/L-kininogens, HKL16 di-
rected to domain D6H of human H-kininogens (29), mAb212 di-
rected to cruzipain-1 (17), and IgG1 myeloma protein (MOPC
31c; Sigma-Aldrich) were used. Antiserum to cruzipain-2 (rab
222) was raised in rabbit chimeric protein, where a fragment (Tyr
147 to Trp 187) from the central domain of cruzipain-2 (20) had
been fused to glutathione transferase.
Cruzipain Isoforms Released by Trypomastigotes. TCTs were
harvested from supernatants of infected Vero cells, washed with
HBSS, and resuspended at 2 3 107 cells/ml in DMEM without
FCS. After incubation at 378C for 2 h, the cell suspension was
centrifuged at 3,000 g, and the supernatant was filtered through
0.2-mm Millipore filters. 200 ml of the supernatant was tested for
proteolytic activity (see above). For the control, 30 mM E-64 (fi-
nal concentration) was added to the supernatants. Immunoab-
sorption of cruzipain isozymes was carried out by treating 600 ml
of the TCT supernatant for 2 h at room temperature with 10% of
protein A–agarose beads (Sigma-Aldrich) previously coated with
10 ml of mAb212 ascites or with 50 ml of rab 222 antiserum. For
controls, irrelevant mAb or preimmune serum was used. After
washing with PBS, the hydrolytic activity associated to the resin
was measured with 50 mM fluorogenic substrate in the presence
or absence of E-64.
Kinin Release Assays. The kinin concentration in reaction
mixtures of human H-kininogen and cruzipain was measured by
competitive ELISA (Markit-M; Dainippon). After activating
stock solutions of Dm28c cruzipain-1 (50 nM) with 2.5 mM
DTT, dilutions of the protease were mixed (2.5–10 nM) with
H-kininogen (10 nM) in 200 ml of a reaction buffer containing
50 mM Na2HPO4, pH 6.5, 200 mM NaCl, 5 mM EDTA, and
0.25 mM DTT. After incubation for 30 min at 378C, the reaction
was stopped by adding 75 mM E-64, 1 mg/ml BSA, and 25 mM
captopril; samples were deproteinized with ice-cold TCA. After
diluting the soluble fractions with the supplier’s buffer, the sam-1292 Kinin Pathway Involved in T. cruzi Infection
ples were applied to the ELISA plate. A standard curve was con-
structed with synthetic BK. Assays with recombinant cruzipain
isozymes (20 nM) were performed as described above. Controls
performed with enzyme buffer alone did not induce kinin re-
lease. The kinin-releasing activity of trypomastigotes was mea-
sured after incubating 10 nM of H-kininogen with TCTs (3 3
106 cells) in 250 ml of Ham’s F12, 12.5 mM Hepes, 25 mM cap-
topril, and 1 mg/ml BSA, pH 6.5, for 30 min at 378C. For the
control, TCTs were preincubated with 75 mM E-64 for 30 min
at 378C before the addition of H-kininogen. The reaction was
stopped by adding E-64 (final concentration of 10 mM) to the
cell suspension. Parasites were centrifuged at 3,000 rpm for 10
min, the supernatants were filtered through 0.2-mm Millipore fil-
ters, and kinin release was quantified as above. Experiments were
done in triplicates.
Results
Trypomastigotes Induce Ca21 Transients in Mammalian Cells
Overexpressing the B2R. Given the evidence that the major
cysteine proteinase from T. cruzi, cruzipain, acts as a kini-
nogenase (23), we set out to investigate if short-lived kinins
were also generated when trypomastigotes interact with
mammalian cells in vitro. As the B2Rs are preferentially
coupled to G proteins of the Gq subtype, we reasoned that
target cells that express elevated levels of this receptor
should swiftly respond to kinins released upon trypomasti-
gote contact. We addressed this question by first examining
if the TCT could trigger [Ca21]i transients in Fura-2–
loaded CHO cells that were transfected with CHO-B2R.
These assays were run in CAP medium to prevent rapid
degradation of the short-lived kinins. Asynchronous and
repetitive [Ca21]i transients were promptly induced z50 s
after TCTs had been added to CHO-B2R (Fig. 1, A, C,
and E). Average responses (Fig. 1 A) involved 67% of the
CHO-B2R exposed to the parasites. The data registered
with two single CHO-B2R cells (Fig. 1, C and E) show
that TCT induces multiple peaks of [Ca21]i, although the
intensity and frequency of the peaks varied from one cell to
another, presumably due to the varying number of produc-
tive contacts established by the parasites. By contrast,
[Ca21]i transients evolved much slower in CHO-mock and
were of low frequency and intensity (Fig. 1, G and H), in-
volving only a small fraction (7%) of the cell population
(Fig. 1 H, average responses). The overall response of
CHO-B2R was markedly reduced when the B2R-selective
antagonist HOE 140 was added to the CAP medium be-
fore the addition of TCTs (Fig. 1, individual cell responses
in D and F, average responses in B), indicating that the
B2R may play an important role for the TCT-induced
[Ca21]i transients. We next evaluated if this signaling path-
way was also engaged when the parasites interact with non-
transfected host cells expressing high levels of endogenous
B2R, such as primary HUVECs. The addition of TCTs to
CAP medium likewise induced [Ca21]i transients in HU-
VECs (Fig. 2, single cell tracing in A and average cell re-
sponses in D). The response, which involved 29% of the
host cells, was markedly reduced by HOE 140 (Fig. 2, B
and E). Control experiments showed that HOE 140 did
not reduce the [Ca21]i transients induced by a-thrombin
(Fig. 2, G and H). Estimates of the cytosolic [Ca21]i by in
vivo calibration methods (28) indicated that the responses
induced by a-thrombin and BK (in both cases involving
nearly 100% of the HUVECs) peaked at z500 and 770
nM, respectively, starting from a base level of z70 nM. By
contrast, HOE 140 attenuated the vigorous [Ca21]i tran-
sients which BK, applied at 250 nM, elicited in HUVECs
(Fig. 2, I and K). These results confirmed that HOE 140
acts as a specific antagonist of B2R in the HUVEC system.
The addition of epimastigotes failed to elicit significant
transients in these cells (Fig. 2, C and F). Collectively, these
data suggest that Dm28c TCT signals in HUVECs through
the constitutively expressed B2R.
Signaling through B2R Increases Host Cell Susceptibility to T.
cruzi Invasion. As it is well established that the induction
of [Ca21]i transients is crucial for invasion by T. cruzi of
many different cell types, we reasoned that the [Ca21]i re-
sponses which TCTs stimulated in CHO-B2R cells may
Figure 1. Trypomastigotes induce [Ca21]i transients in CHO cells
through the B2R. The changes of [Ca21]i were determined on CHO-
mock or CHO-B2R preloaded with Fura 2-AM in Ham’s F12 medium
supplemented with 1 mg/ml of BSA, 12.5 mM Hepes, and 25 mM capto-
pril. The tracings represent cytosolic [Ca21]i transients that addition of
TCTs (parasite/host cell ratio of 10:1) induces in either a single cell or av-
erage responses of 20–30 cells. (A) TCTs (arrow) added to CHO-B2R,
average responses. (B) TCTs added to CHO-B2R that were pretreated
for 200 s with 100 nM HOE 140 (left arrow), average responses. (C and
E) TCTs added to CHO-B2R, individual cell response. (D and F) TCTs
added to CHO-B2R pretreated with HOE 140, individual cell responses.
(G) TCTs added to CHO-mock, individual cell responses. (H) TCTs
added to CHO-mock, average responses. CHO-mock failed to induce
significant [Ca21]i elevations upon BK application (up to 50 nM).1293 Scharfstein et al.
have increased their susceptibility to infection. Consistent
with this prediction, the invasion index for CHO-B2R in
the presence of CAP medium was nearly 4.5-fold higher
than that for CHO-mock (Fig. 3 A), whereas captopril had
no effect on the invasion of CHO-mock (not shown).
Similarly to the inhibitory effects of HOE 140 on TCT-
induced [Ca21]i transients, addition of the B2R antagonist
decreased the invasion of CHO-B2R in CAP medium,
whereas it had no effect on the invasion of CHO-mock
(Fig. 3 A). Similar effects were noted when we attempted
to downregulate B2R by applying high concentrations of
the agonist, i.e., 0.1 mM BK, to these cultures. Using pri-
mary cultures of HUVECs, we noted that parasite invasion
was enhanced threefold in the presence of 25 mM capto-
pril, whereas absence of captopril or inclusion of HOE 140
in CAP medium significantly attenuated invasion (Fig. 3
B). Although HUVECs were less sensitive to invasion than
CHO-B2R, TCT invasion of HUVECs in the presence of
CAP medium was likewise reduced by the addition of high
concentrations (0.1 mM) BK (Fig. 3 B). In conclusion,
TCT invasion of target cells that overexpress B2R is mark-
edly enhanced in the presence of captopril, suggesting that
the short-lived kinin agonist is protected from degradation
by the kininase II inhibitor.
Processing of Cell-bound Kininogens Is Required for TCT In-
vasion. The fact that TCT invasion is potentiated by
kininase II inhibitors and reduced in cultures exposed to
specific B2R antagonist or to high levels of exogenous BK
pointed to the possibility that a low amount of plasma ki-
ninogen either remains associated with the cell surfaces of
target cells and/or is displayed by the parasites, in either
way serving as a source for precursors of kinin-signaling
peptides. Consistent with this concept, the addition of an
exogenous supply of H-kininogen (9 nM) to the serum-
free CAP medium resulted in a greater than threefold
increase in parasite invasion (Fig. 4 A). To test the hypoth-
esis that HUVEC susceptibility to TCT invasion is influ-
enced by the levels of kinin precursors and to further
substantiate our notion that kinins are indeed involved in
the signaling mechanism, we tested the effects of an mAB
(MBK3) to BK that cross-reacts with the kinin segment of
human and bovine kininogens (27). Our data show that
Figure 2. TCTs induce cytosolic [Ca21]i transients in
HUVECs through the B2R. The changes in [Ca21]i were
determined by adding TCTs (parasite/host cell ratio of 10:1)
to monolayers of HUVECs preloaded with Fura 2-AM,
loaded, plated on gelatin-coated glass coverslips, main-
tained in M199 medium with 12.5 mM Hepes, 1 mg/ml
BSA, and 25 mM captopril. (A) TCTs added to HUVECs,
average responses; (D) individual cell response; (B) TCTs
added to HUVECs that were previously treated with 100
nM HOE 140, average cell responses; (E) individual cell
response; (C) epimastigotes (EPI) added to HUVECs, av-
erage responses; (F) epimastigotes added to HUVECs, in-
dividual cell responses. (G–I) Internal controls showing
the sensitivity of HUVECs to BK and selectivity of the
B2R antagonist HOE 140. Tracings represent average cell
responses. (G) Cytosolic [Ca21]i changes induced by 14
nM a-thrombin; (H) effect of 100 nM HOE 140 on
thrombin-induced responses; (I) responses induced by 5
nM BK; (K) effect of 100 nM HOE 140 on responses in-
duced by BK.
Figure 3. T. cruzi invasion is enhanced in mammalian
cells overexpressing B2R. (A) Invasion assays were per-
formed with CHO-B2R or CHO-mock in HAM’s F12
medium containing 1 mg/ml of BSA in the presence or
absence of 25 mM captopril. Dm28c TCTs were added at
a ratio of 2:1 (parasite vs. CHO) and the interaction pro-
ceeded for 3 h at 378C in the presence or absence of 100
nM HOE 140 or BK, as indicated. (B) TCTs were added
to HUVECs (ratio of 2:1) in M199 medium containing 1
mg/ml BSA. The interaction proceeded for 3 h in the
presence or absence of 25 mM captopril. HOE 140 or BK,
100 nM each, was added to the CAP medium immedi-
ately before addition of the parasites. Values represent the
number of intracellular parasites per 100 cells as means 6
SD of three independent experiments. Significant differ-
ences (P , 0.05) between paired bars are marked by aster-
isks (*/*; **/**).1294 Kinin Pathway Involved in T. cruzi Infection
preincubation of HUVECs with 300 nM MBK3 in CAP
medium significantly reduced the potentiating effects of
captopril, whereas the addition of unrelated Ab (IgG1)
failed to interfere with TCT invasion, and HKL16, an
mAb directed to an epitope of kininogen domain D6H,
had only marginal inhibitory activity (Fig. 4 B). The re-
sults suggest that MBK3 compromises parasite invasion of
HUVECs, either by blocking the processing of cell-bound
kininogens and/or by “neutralizing” the liberated effector
kinin peptide.
E-64–sensitive Proteases Mediate Kinin Release by Living
Trypomastigotes. Given the indications that the major cys-
teine proteinase isoform, cruzipain-1, releases kinins from
H-kininogen (23), and that an accessible BK epitope is re-
quired for parasite invasion (Fig. 4 B), we sought to exam-
ine if living trypomastigotes are able to release kinins from
purified H-kininogen. To this end, washed TCTs were re-
suspended in CAP medium and 10 nM of purified H-kinin-
ogen was added to the suspension. ELISA measurements of
the kinin concentrations in culture supernatants revealed
the presence of this peptide within 30 min (Fig. 5 A). The
processing reaction, which evolved in the absence of re-
ducing agents, converted a small fraction (z10%) of avail-
able H-kininogens into immunoreactive kinins over a lim-
ited time period. Significantly, the kinin-releasing activity
was completely abolished by pretreating the parasites with
an irreversible inhibitor of cysteine proteinases, E-64.
These data suggest that TCTs engage cysteine proteinases
in releasing kinins from soluble H-kininogens. As trypo-
mastigotes are poorly endocytic (30), the membrane-imper-
meable E-64 inhibitor either binds to secreted cysteine
proteases or acts on activated enzymes as they reach the
parasites’ flagellar pocket (17).
Trypomastigotes Release Different Cruzipain Isoforms. As
pointed out in a previous study (23), the Met-Lys and Arg-
Ser flanking site bonds of BK are cleaved at different effi-
ciencies by two distinct recombinant cruzipain isoforms,
namely cruzain (cruzipain-1) and cruzipain-2. Assays per-
formed with each of these genetically engineered protein-
ases (both truncated on the COOH-terminal extension)
confirmed that they are able to release immunoreactive ki-
nins from purified H-kininogen, albeit with different effi-
ciencies (Fig. 5 B). Consistent with the demonstration of ki-
nin-releasing activity by living trypomastigotes, analysis of
the supernatants from parasite suspensions revealed the pres-
ence of peptidases that were activated by DTT and inhibited
by E-64 (Fig. 6 A). Immunoprecipitation using isoform-
specific Abs mAb212 (anti–cruzipain-1) and rab 222 (anti–
cruzipain-2) followed by fluorogenic substrate assay sug-
gested that both isoforms were present in the supernatants
(Fig. 6 B). Hence, TCTs released cysteine protease isoforms
that may be involved in parasite-induced kinin release.
The Kinin Pathway of Parasite Invasion Is Linked to the Ex-
pression of Cruzipain-1. As both recombinant cruzipain-1
and cruzipain-2 act as kininogenases in vitro, we investi-
gated if the engagement of B2R by the TCT may be linked
to differential expression of these isoforms. To this end, we
used the episomal pTEX plasmid to generate TCT trans-
fectants containing full-length copies of the gene encoding
for the major cruzipain-1 isoform (TCT-cz1) or for the
Figure 4. H-kininogen potentiates parasite invasion of HUVECs. (A)
The effects of addition of H-kininogen on parasite invasion. Interaction
was carried out in CAP medium at a parasite/host cell ratio of 2:1 for 3 h
in the presence or absence of 9 nM H-kininogen. Data are expressed as
means 6 SD of three independent experiments. The statistical signifi-
cance between pairs of data is indicated by asterisks (P , 0.05). (B) The
effects of mAbs directed against different kininogen epitopes. CAP me-
dium was supplemented with 200 nM MBK3, IgG1 myeloma protein
(MOPC 31c), or HKL6, and the interaction was carried out at a ratio of
5:1 (parasites/host cells) for 3 h. Results are expressed as percentage of in-
hibition of invasion, in relation to values obtained in cultures containing
CAP medium alone.
Figure 5. Kinin-releasing activity of TCTs and recom-
binant cruzipain isoforms. (A) Freshly released parasites,
harvested from supernatants of Vero cultures maintained in
DMEM-FCS, were washed and resuspended in Ham’s F12
medium containing 12.5 mM Hepes, 1 mg/ml of BSA,
and 25 mM captopril at pH 6.5. Purified H-kininogen (10
nM, final concentration) was added to 250 ml of the para-
sites (3 3 106 cells), and the suspension was incubated at
378C for 30 min. Involvement of cysteine proteases was
examined by preincubating the TCTs in medium supple-
mented with E-64 (75 mM). After removing the parasites
by centrifugation (3,000 rpm for 15 min at 48C), the su-
pernatants were filtered, deproteinized with ice-cold TCA,
and the kinin concentrations were determined by a com-
petitive ELISA. (B) Kinin-releasing activity of recombi-
nant cruzipain-1 or cruzipain-2. The reaction was carried
out by incubating each of the recombinant proteases (20 nM) with H-kininogen (10 nM) in 200 ml of 50 mM Na2HPO4, pH 6.5, 200 mM NaCl, 5 mM
EDTA, and 0.25 mM DTT for 2 h at 378C. Controls were carried out by preinactivating the proteinases with E-64. Values represent the mean 6 SD of
three independent assays.1295 Scharfstein et al.
cruzipain-2 gene (TCT-cz2). Consistent with the higher
stability of recombinant cruzipain-2 at alkaline pH (Lima,
A.P.C.A., unpublished observations), we found that a sig-
nificant proportion of the overall cysteine proteinase activ-
ity present in TCT-cz2 lysates (30%) was attributed to en-
zymes that resist inactivation at pH 12 (Fig. 6 C), whereas
only a minor fraction (8%) of alkaline-resistant cysteine
peptidases were present in TCT-cz1 (not shown) or wild-
type cells (Fig. 6 C). Hence, the profile of isoforms ex-
pressed by TCT-cz2, although still dominated by the alka-
line-sensitive major cruzipain-1 isoform, is skewed towards
increased production of the cruzipain-2–like isoforms. Re-
markably, invasion assays performed with target cells that
do not overexpress B2R, i.e., CHO-mock or Vero cells,
revealed that TCT-cz1 was consistently less infective (ex-
emplified for CHO-mock; Fig. 6 D, gray bar at left) com-
pared with TCT-cz2 (Fig. 6 D, gray bar at right) or wild-
type parasites (Fig. 3 A). TCT-cz1 efficiently invaded
CHO-B2R cells, and this effect was reduced almost to the
reference level of CHO-mock by the addition of HOE 140
(Fig. 6 D, black bars at right), indicating that the B2R path-
way is used by the cz1 transfectants. By contrast, overex-
pression of cruzipain-2 did not significantly enhance inva-
sion of CHO-B2R cells compared with CHO-mock (Fig.
6 D, right). Furthermore, HOE 140 did not reduce TCT-
cz2 infectivity for CHO-B2R (Fig. 6 D, right), suggesting
that these parasites signal through kinin-independent path-
ways. Collectively, these data suggest that T. cruzi’s ability
to engage the kinin signaling pathway of invasion is prefer-
entially linked to a dominant expression of the major cys-
teine proteinase isoform (cruzipain-1).
Purified Cruzipain Triggers [Ca21]i Transients in Cells Ex-
pressing B2R. Given the indications that cruzipain-1 is
found in the supernatants from wild-type TCTs and that
living trypomastigotes release kinins through E-64–sensi-
tive protease(s), we tested the ability of purified cruzipain-1
to induce [Ca21]i transients. Indeed, we found that the par-
asite proteinase triggered robust [Ca21]i transients in CHO-
B2R loaded with Fura-2 (Fig. 7 B). This response was al-
most nullified by adding HOE 140 at 50 nM (Fig. 7 D) to
the CAP medium, whereas [des Arg9-Leu8-BK], an antag-
onist of the B1R subtype, failed to interfere (data not
shown). Importantly, the catalytic activity of cruzipain-1
was essentially required for the B2R stimulation because
pretreatment with E-64 abrogated the [Ca21]i response
(Fig. 7 C). These data suggest that cruzipain-1 generates a
kinin-like signaling factor by processing kininogen dis-
played by CHO cells. Unlike the strong [Ca21]i transients
in CHO-B2R, cruzipain-1 induced only a minor [Ca21]i
response in CHO-mock (Fig. 7 A). This low response was
not inhibited by HOE 140 or by [des Arg9-Leu8-BK] (data
not shown), suggesting that the minor [Ca21]i transients in-
Figure 6. Differential infectivity of TCTs
overexpressing cruzipain isoforms. (A)
Analysis of the cysteine protease activity
present in supernatants from wild-type
Dm28c TCTs. Parasite suspensions (2 3 107
cells/ml) were incubated at 378C for 2 h in
DMEM without FCS. The filtered superna-
tants were tested for peptidase activity at
378C using 20 mM  e-NH2-Cap-Leu-
(SBz)Cys-MCA in 50 mM Na2HPO4, pH
6.5, 200 mM NaCl, 5 mM EDTA, and 5
mM DTT. The graph depicts enzyme activ-
ity found in trypomastigote supernatants
(Supnt) activated with DTT (j) or pre-
treated with 30 mM E-64 (d). (B) Protein
A–agarose beads were loaded with anti–
cruzipain-1 or anti–cruzipain-2 and the im-
munobeads were added to supernatants ob-
tained from wild-type TCT suspensions.
After 2 h of incubation at room tempera-
ture, the immune complexes associated with
the beads were washed with PBS and the
initial rates of hydrolysis by enzymes associ-
ated with the solid phase were monitored in
the presence or absence of 30 mM E-64, as
specified above. Results (initial rates) are
represented by the mean of three indepen-
dent experiments. (C) The alkaline pH sta-
bility of the cysteine proteases from wild-
type (WT) Dm28c TCTs or TCT-cz2 was
assessed by mixing 2 ml of the Triton X-100 lysates (1 mg/ml of protein) with 100 ml of 0.1 M glycine buffer, pH 12. After 5 s, the lysates were diluted
in the reaction buffer and the residual E-64–sensitive peptidase activity was measured for TCT-cz2 transfectants or wild-type parasites with e-l-NH2-
Cap-l-(SBz)C-MCA. Gray bars depict rates obtained after alkaline treatment of lysates. The values for initial rates of hydrolysis are expressed as means ±
SD of three independent experiments. (D) Invasion assays performed by adding the TCT-cz1 or TCT-cz2 transfectants to monolayers of CHO-B2R
(black bars) or CHO-mock (gray bars) in Ham’s F12 medium containing 1 mg/ml of BSA in the presence of 25 mM captopril for 3 h at a parasite/host
cell ratio of 2:1. Assays were carried out in the presence or absence of 100 nM HOE 140 as indicated, and the number of intracellular parasites per 100
cells was calculated. Results are given as means ± SD of three independent experiments. Statistical significance (P , 0.05) is indicated by asterisks.1296 Kinin Pathway Involved in T. cruzi Infection
duced in CHO-mock resulted from a kinin-independent
signaling pathway.
Parasite Invasion of HUVECs Is Enhanced by BK or by
Cruzipain. To further investigate the interrelation be-
tween cruzipain activity and the parasite’s ability to invade
target cells by the kinin pathway, dose–response curves
were separately established for BK (up to 100 nM) or for
purified cruzipain. Parasite invasion peaked at 1 nM BK,
whereas higher concentrations significantly reduced inva-
sion to levels even below baseline, most likely due to re-
ceptor desensitization (Fig. 8 A). Thus, stimulation of B2R
by kinin concentrations in the low nanomolar range signif-
icantly increases HUVECs’ susceptibility to invasion by T.
cruzi, whereas higher concentrations of the same peptide
protected the host cells. Given that cruzipain-1 is able to
release kinins from soluble H-kininogen (Fig. 8 B) and that
it induces potent [Ca21]i transients through B2R (Fig. 7),
we checked if variations in the levels of activated protease
could likewise influence the effectiveness of the invasion
process. HUVEC invasion was modulated upon addition of
increasing concentrations of cruzipain-1 to CAP medium,
peaking at 5 nM activated protease (Fig. 8 C). The similar
concentration range observed for peak activities of exoge-
nous BK and purified cruzipain-1 suggests that the parasite
competence to generate the kinin agonist may be influ-
enced by quantitative and/or qualitative differences of cys-
teine protease expressed by the parasite. As a further
attempt to characterize the involvement of the kinin-
releasing cysteine proteases in the invasion process, the ef-
fects of synthetic or natural cysteine protease inhibitors
were investigated. Unexpectedly, addition of E-64, an irre-
versible inhibitor of papain-like enzymes, failed to protect
HUVECs from infection even when tested at 75 mM (<1%
inhibition; Fig. 8 D). Likewise, invasion was not impaired
in cultures either supplemented with leupeptin (10 mM) or
by cystatin C (1 mM), a tight binding protein inhibitor
present in human plasma. Considering the facts that (a) E-64
prevents kinin release from H-kininogen by TCTs (Fig. 5
A), and that (b) trypomastigotes are poorly endocytic in cell
suspensions (30), we reasoned that the failure of mem-
brane-impermeable cruzipain inhibitors to impair invasion
could be an indication that kinin liberation occurs within
the secluded sites formed by the juxtaposition of host and
parasite plasma membranes. To address this possibility, we
tested the effects of a membrane-permeable, irreversible in-
hibitor of cruzipain, Z-(SBz)Cys-Phe-CHN2 (15) and
found that it effectively inhibited (85%) HUVEC invasion,
the extent of protection conferred by this compound being
higher than that observed with HOE 140 (Fig. 8 D).
Discussion
In this study, we demonstrate that trypomastigote inva-
sion of host cells expressing BK B2Rs is drastically increased
due to signaling by kinin peptides. The presence of capto-
pril in the culture medium was a crucial prerequisite for the
increased invasiveness of target cells expressing B2R, most
likely because BK was protected from rapid degradation by
ACE/kininase II (31). The effects induced by captopril
suggest that T. cruzi tissue tropism may be influenced by
variable levels and activities of kinin-degrading peptidases
expressed in different host tissues. Indeed, highly vascular-
ized tissues such as kidney parenchyma and lungs abun-
dantly expressing ACE (32) are virtually spared from T.
cruzi parasitism, whereas other tissues undergo massive in-
fection and destruction during acute infection (33). Thus,
variable expression levels of ACE may modulate the sever-
ity of lesions and fibrosis induced by this pathogen in the
cardiovascular system of chagasic patients.
Because the presence of captopril or HOE 140 did not
interfere with parasite invasion of CHO-mock (this study),
Vero cells (not shown), or L6E9 myoblasts (Docampo, R.,
personal communication), parasites likely invade these cell
lines by alternative mechanisms such as the TGF-b–depen-
dent transducing pathway (7) or oligopeptidase B–mediated
production of [Ca21]i signaling agonists (13, 14). Whereas
the latter pathway is thought to involve proteolytic pro-
cessing of a cytoplasmic precursor protein of the parasite
(14), the kinin-mediated signal transduction route de-
scribed herein likely depends on the processing of a host-
derived precursor, namely kininogen(s). Preliminary analy-
sis of a limited panel of well-established T. cruzi strains and
clones indicates that invasion through the kinin-transduc-
ing pathway is not ubiquitous (Scharfstein, J., unpublished
observations), indicating that clones from this highly di-
verse parasite species (34–37) may vary with respect to the
ability to release proinflammatory kinins.
Figure 7. Cruzipain induces [Ca21]i transients in CHO cells through
the B2R. Activated cruzipain-1 or E-64–treated cruzipain-1 were added
to monolayers of CHO cells in Ham’s F12 medium supplemented with 1
mg/ml of BSA, 25 mM captopril. The protease was diluted 10-fold to 5
nM. (A) CHO-mock; (B) CHO-B2R exposed to cruzipain; (C) CHO-
B2R exposed to E-64–treated cruzipain; (D) CHO-B2R pretreated with
100 nM HOE 140 for 120 s and then exposed to cruzipain-1 (indicated
by arrows). Addition of the proteinase buffer alone did not elicit any
[Ca21]i transients in CHO cells. The y-axis represents the ratio of fluores-
cent absorbances at 334 and 380 nm. The tracings represent average cell
responses.1297 Scharfstein et al.
One of the conundrums of this study is the source of ki-
ninogens involved in the invasion process. Kininogens are
secretory proteins displaying high affinity binding sites for
heparan sulfate proteoglycans exposed on most cell surfaces
(38), and thus we speculate that serum-derived kininogens
attach to HUVECs or CHO cells during cultivation in
vitro. At first sight, the finding that purified cruzipain is able
to release kinins from cell-bound kininogens seems para-
doxical because papain-like enzymes are rather sensitive to
inhibition by the cystatin-like domains of kininogens (39).
However, it is well known that the cystatin inhibitory sites
in domain D3 of kininogen’s heavy chain overlaps with the
cell binding site that docks it to endothelial cells (40), and
therefore may not be available for cruzipain inhibition. Our
finding that FITC-labeled cruzipain failed to bind to HU-
VECs (data not shown) is consistent with this interpreta-
tion. Further, our demonstration that activated cruzipain
stimulates vigorous Ca21 transients in CHO-B2R, and that
HOE 140 and E-64 block this effect, points to proteolytic
release of kinin agonists, either directly by secreted forms of
the proteinase or indirectly by the activation of a kallikrein-
like zymogen (23). We have previously shown that cruzi-
pain-2 efficiently cleaves the NH2-terminal flanking site of
BK in kininogen domain D4, whereas the major isoform,
cruzain, herein referred as cruzipain-1, preferentially cleaves
the COOH-terminal flanking site (23). In this study, we
show the presence of both isozymes in TCT supernatants;
however, invasion assays performed with TCT transfectants
showed that overexpression of the major isoform cruzipain-1,
but not of cruzipain-2, favors the engagement of the kinin-
mediated invasion pathway. Hence, our findings point to a
causal link between parasitic protease cruzipain-1 and host
kinin signaling pathway.
Previous studies have revealed that [Ca21]i transients in-
duced by G protein–coupled receptor agonists stimulate
the recruitment and fusion of lysosomes to the plasma
membrane at sites where trypomastigotes are attached to
host cells (4, 5). Considering that adhesive interactions be-
tween TCTs and host cells favor their reciprocal activation
(41), it is conceivable that kinin signaling is most effective
when the processing reaction is restricted to sites formed by
juxtaposition of host and parasite cell membranes. Hence,
signals emanating from host contacts with a few trypomas-
tigotes, e.g., in CHO-mock or in HOE 140–treated
CHO-B2R, may promote the delivery of host lysosomal
cargos to secluded intercellular spaces, and this incipient ac-
tivation process may generate a reduced environment in
these segregated sites thereby sustaining activation of cruzi-
pain-type kininogenases. The finding that membrane-per-
meable cysteine proteinase inhibitor Z-(SBz)Cys-Phe-CHN2,
but not hydrophilic inhibitor E-64, conveyed partial albeit
significant protection of HUVECs, is consistent with such a
“dual signaling” model.
As B2R is constitutively expressed by endothelial cells,
smooth muscle, fibroblasts, epithelial cells, and neuronal
cells (24), and the B1 subtype of kinin receptors is upregu-
lated during inflammation (42), increased cellular invasion
may be just one example of a physiopathological response
Figure 8. The involvement of cruzipain in parasite in-
vasion. (A) TCTs were added to HUVECs (parasite/host
cell ratio of 5:1) in M199 CAP medium containing BK (0,
10, 50, and 100 nM) and incubated at 378C for 3 h. (B)
The graph illustrates the dose dependence of kinin-releas-
ing activity of cruzipain-1. Enzyme stocks (50 nM) preac-
tivated with DTT were subsequently diluted to the appro-
priate concentration in 50 mM Na2HPO4, pH 6.5, 5 mM
EDTA, and 0.25 mM DTT supplemented with 10 nM
H-kininogen. After a 30-min incubation at 378C, the re-
action was stopped by the addition of 75 mM E-64 and 25
mM captopril. Kinin release by activated cruzipain-1 (d)
or E-64–treated cruzipain-1 (r) was determined by com-
petitive ELISA. Controls carried out with buffer in the ab-
sence of cruzipain did not lead to kinin release. (C) Inva-
sion assays were carried out by adding aliquots of
preactivated cruzipain-1 (50 nM stocks) to CAP medium
before addition of TCTs to HUVECs (parasite/host cell
ratio of 5:1, 1 h). (D) Invasion assays carried out at a para-
site/host cell ratio of 5:1 for 3 h in CAP medium supple-
mented with Z-(SBz)Cys-Phe-CHN2 (10 mM), E-64 (75
mM), leupeptin (10 mM), cystatin C (1 mM), and HOE
140 (100 nM). The addition of DMSO vehicle (1%) did
not interfere with invasion. The activity of each com-
pound was expressed as the percentage of inhibition of
parasite invasion with reference to assays performed in
CAP medium alone. Data are expressed as means 6 SD of
at least three independent experiments. The statistical anal-
ysis was done by one-way analysis of variance; significance
was considered at *P , 0.05.1298 Kinin Pathway Involved in T. cruzi Infection
that kinins and their metabolites may induce in tissues
exposed to T. cruzi. For example, triggering of kinin re-
ceptors from vascular endothelial cells may facilitate the
transmigration of the trypomastigotes across capillaries,
modulate the expression of vascular adhesion molecules,
and/or promote plasma leakage into interstitial spaces, and
thus contribute to the microvascular changes observed in
patients with chronic cardiomyopathy (43). Unraveling the
delicate interplay between the parasite cysteine proteinases
and the multiple components of the kinin cascade system
may provide fresh insights into the molecular pathogenesis
of Chagas’ disease.
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